Gencor has announced its newly published randomised, double-blind, placebo-controlled clinical study has demonstrated that PlexoZome Levagen, a topical liposomal formulation of palmitoylethanolamide (PEA), provides safe and effective relief of post-exercise knee joint discomfort.
"This is the first published clinical trial to show that topical application of PEA can provide rapid and meaningful aches and discomfort relief," said Dr. Amanda Rao, lead investigator of the study. "The findings highlight PlexoZome Levagen as a promising natural analgesic alternative, particularly for individuals seeking fast-acting and well-tolerated solutions."
The peer-reviewed study, published in the Journal of Alternative, Complementary & Integrative Medicine, enrolled 86 healthy adults who experienced knee discomfort following exercise. Upon a knee pain rating of ≥3/10 on the VAS pain scale, participants applied three sprays of their investigational product (PlexoZome Levagen PEA or placebo). Participants recorded their pain on the VAS every 15 minutes for a maximum of 2 hours or until their pain subsided. If participants were still experiencing pain, they reapplied their investigational product at the 30-, 60-, and 90-minute marks—a total of 214 pain episodes qualified for analysis. The results showed that the PEA group significantly resolved more pain events within 60 minutes of onset compared with the placebo. At 60 minutes, the PEA group experienced a 71% reduction in pain from baseline, compared to a 43% reduction in the placebo group.
"The clinical research results support the growing demand for topical, non-NSAID solutions in the sports nutrition, active lifestyle, and joint health markets," said Ramasamy Venkatesh, Managing Director of Gencor Pacific. “With its liposomal delivery system, PlexoZome Levagen ensures enhanced absorption of PEA at the targeted site of discomfort, offering brands a clinically validated, innovative ingredient to differentiate their product portfolios.”
PlexoZome Levagen is a patented liposomal formulation of palmitoylethanolamide (PEA), a naturally occurring fatty acid amide with well-documented analgesic and anti-inflammatory properties. Leveraging Pharmako Biotechnologies’ advanced liposomal delivery system, PlexoZome, the combination provides targeted, rapid relief for joint and muscle aches at a low dosage of 1.8mg per spray.
